SMMT Valuation

Summit Therapeutics Inc

Add to Watchlist

Advanced Chart

26.010

+0.14(0.541%)1D

Overview
Forecast
Valuation
Earnings

SMMT Relative Valuation

SMMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SMMT is overvalued; if below, it's undervalued.

Historical Valuation

Summit Therapeutics Inc (SMMT) is now in the Fair zone, suggesting that its current forward PS ratio of 226.12 is considered Fairly compared with the five-year average of -16.47. The fair price of Summit Therapeutics Inc (SMMT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：26.01

Fair

-33.55

Trailing

Forward

-36.92

EV/EBITDA

Summit Therapeutics Inc. (SMMT) has a current EV/EBITDA of -36.92. The 5-year average EV/EBITDA is -12.49. The thresholds are as follows: Strongly Undervalued below -54.54, Undervalued between -54.54 and -33.52, Fairly Valued between 8.53 and -33.52, Overvalued between 8.53 and 29.56, and Strongly Overvalued above 29.56. The current Forward EV/EBITDA of -36.92 falls within the Undervalued range.

-29.69

EV/EBIT

Summit Therapeutics Inc. (SMMT) has a current EV/EBIT of -29.69. The 5-year average EV/EBIT is -18.63. The thresholds are as follows: Strongly Undervalued below -58.51, Undervalued between -58.51 and -38.57, Fairly Valued between 1.31 and -38.57, Overvalued between 1.31 and 21.24, and Strongly Overvalued above 21.24. The current Forward EV/EBIT of -29.69 falls within the Historic Trend Line -Fairly Valued range.

226.12

Summit Therapeutics Inc. (SMMT) has a current PS of 226.12. The 5-year average PS is 352.35. The thresholds are as follows: Strongly Undervalued below -827.93, Undervalued between -827.93 and -237.79, Fairly Valued between 942.49 and -237.79, Overvalued between 942.49 and 1532.63, and Strongly Overvalued above 1532.63. The current Forward PS of 226.12 falls within the Historic Trend Line -Fairly Valued range.

-74.89

P/OCF

Summit Therapeutics Inc. (SMMT) has a current P/OCF of -74.89. The 5-year average P/OCF is -21.77. The thresholds are as follows: Strongly Undervalued below -98.57, Undervalued between -98.57 and -60.17, Fairly Valued between 16.63 and -60.17, Overvalued between 16.63 and 55.03, and Strongly Overvalued above 55.03. The current Forward P/OCF of -74.89 falls within the Undervalued range.

-46.16

P/FCF

Summit Therapeutics Inc. (SMMT) has a current P/FCF of -46.16. The 5-year average P/FCF is -7.81. The thresholds are as follows: Strongly Undervalued below -44.85, Undervalued between -44.85 and -26.33, Fairly Valued between 10.71 and -26.33, Overvalued between 10.71 and 29.23, and Strongly Overvalued above 29.23. The current Forward P/FCF of -46.16 falls within the Strongly Undervalued range.

Summit Therapeutics Inc (SMMT) has a current Price-to-Book (P/B) ratio of 74.07. Compared to its 3-year average P/B ratio of 31.94 , the current P/B ratio is approximately 131.90% higher. Relative to its 5-year average P/B ratio of 21.37, the current P/B ratio is about 246.62% higher. Summit Therapeutics Inc (SMMT) has a Forward Free Cash Flow (FCF) yield of approximately -1.10%. Compared to its 3-year average FCF yield of -5.13%, the current FCF yield is approximately -78.54% lower. Relative to its 5-year average FCF yield of -12.72% , the current FCF yield is about -91.34% lower.

74.07

P/B

Median3y

31.94

Median5y

21.37

-1.10

FCF Yield

Median3y

-5.13

Median5y

-12.72

Competitors Valuation Multiple

The average P/S ratio for SMMT's competitors is 62.68, providing a benchmark for relative valuation. Summit Therapeutics Inc Corp (SMMT) exhibits a P/S ratio of 226.12, which is 260.72% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SMMT.O

Summit Therapeutics Inc

Neurocrine Biosciences Inc

BioMarin Pharmaceutical Inc

Performance Decomposition

Market capitalization of SMMT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SMMT in the past 1 year is driven by Unknown.